Genomic Vision

Genomic Vision Debt

The Debt of Genomic Vision (GV.PA) as of Oct 24, 2026 is 2.44 M EUR. In the previous year, Debt was 994,000.00 EUR — a change of 145.07% (higher).

Debt

2.44 MEUR

YoY

145.07%

Last updated:

In 2022, Genomic Vision's total debt was 2.44 M EUR, a 145.07% change from the 994,000.00 EUR total debt recorded in the previous year.

The Genomic Vision Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2015
20,000.00 EUR
Jan 1, 2016
0.00 EUR
Jan 1, 2017
930,000.00 EUR
Jan 1, 2018
550,000.00 EUR
Jan 1, 2019
108,000.00 EUR
Jan 1, 2020
1.14 M EUR
Jan 1, 2021
994,000.00 EUR
Jan 1, 2022
2.44 M EUR
The Genomic Vision Debt history
YEARDebtYoY
2.44 MEUR+145.07%
994,000.00EUR-12.42%
1.14 MEUR+950.93%
108,000.00EUR-80.36%
550,000.00EUR-40.86%
930,000.00EUR—
0.00EUR-100.00%
20,000.00EUR-97.47%
790,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Debt Details

Understanding Genomic Vision's Debt Structure

Genomic Vision's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Genomic Vision's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Genomic Vision’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Genomic Vision’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Genomic Vision stock

Debt of Genomic Vision is 2.44 M EUR in 2022.

Debt of Genomic Vision changed from 994,000.00 EUR to 2.44 M EUR, representing a 145.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Genomic Vision historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Genomic Vision

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genomic Vision